Alloy Women’s Health is a leading player in perimenopause, menopause and sexual healthcare, providing expert information and education, science-backed solutions and community to help women better manage symptoms and increase their overall quality of life. Alloy provides a suite of prescription medications including hormone replacement therapy (HRT), skin and hair care treatments, and more. They offer consultations with menopause-trained physicians in all 50 states, followed by personalized treatments, ongoing care via unlimited messaging and access to support groups. Alloy is affordable compared to alternatives, with a $50 annual fee and prescriptions starting at $40 a month.
In the US, more than 1M women transition into menopause each year, but lack the proper resources and medication to manage their symptoms. Despite being a universal experience for women, the complex and individualized nature of menopausal symptoms, which can vary widely from woman to woman, make finding the right treatment challenging.
Alloy is addressing this pain-point by providing quality, accessible, and affordable care through the convenience of tech-enabled services. When it comes to systemic hormone therapy, Alloy does not deviate from what is highly-regulated and evidence backed. They innovate in areas where pharmacies do not profit: products like their estriol face cream and sexual atrophy cream. These products are not widely available commercially and therefore Alloy makes their own validated, compounded products.
Founded by Anne Fulenwider and Monica Molenaar, the Alloy team combines talent and passion from across disciplines with decades of experience at organizations like NYU Langone, Columbia Medical School, Harvard and Stanford including a group of OB/GYNs led by Alloy’s Chief Medical Advisor Dr. Sharone Malone. Dr. Malone is a New York Times bestselling author, renowned expert in women’s health, and vocal advocate for menopause awareness and evidence-based information about hormone replacement therapy.
Anne Fulenwider, Co-Founder of Alloy, said:
“Amboy Street Ventures recognizes the importance of the work we are doing at Alloy to revolutionize women’s healthcare, particularly during the critical stage of menopause. This investment will allow us to expand our offerings and provide even more women with the care and resources they deserve. We’re proud to be at the forefront of this movement, providing access to scarce expertise and delivering accessible, evidence-based solutions that make a real difference in women’s lives, and so grateful for the support.”
Monica Molenaar, Co-Founder of Alloy, added:
"Menopause has long been a misunderstood and underserved aspect of women’s health, and Alloy is proud to be changing that narrative. With the support of Amboy Street Ventures, we are empowered to accelerate our growth, develop new products, and reach even more women. Our team’s deep expertise and passion for women’s health will continue to drive our efforts to improve the quality of life for women everywhere."
Since its launch in 2021, Alloy has served thousands of women who report feeling better after just 2 weeks. They have assembled a team of doctors who are menopause specialists (and advocates) and quality care providers and have attracted the attention of the media, celebrities and investors. Amboy Street is excited to support Alloy alongside notable co-investors Kairos Investments, Emmeline and PACE Healthcare Capital. With the funding, Alloy will continue to build out their pipeline of menopause, skin and hair, and sexual health care products, including a new line of weight management offerings.
Alloy is one of ASV’s growing portfolio of brands pioneering women’s health and sexual health solutions alongside Hey Jane, leading telehealth abortion provider, Contraline, the maker of male birth control and Dame Products, a leading female-focused sexual wellness brand. See the full portfolio here. To learn more about Alloy visit www.myalloy.com
